LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS… Read more
LakeShore Biopharma Co., Ltd (LSB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2022: -0.001x
Based on the latest financial reports, LakeShore Biopharma Co., Ltd (LSB) has a cash flow conversion efficiency ratio of -0.001x as of June 2022.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-693.96K) by net assets ($1.27 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
LakeShore Biopharma Co., Ltd - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how LakeShore Biopharma Co., Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
LakeShore Biopharma Co., Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LakeShore Biopharma Co., Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trillion Energy International Inc.
OTCQB:TRLEF
|
-0.030x |
|
Plus Tech Innovation PCL
BK:PTECH
|
-0.041x |
|
Delixy Holdings Limited Ordinary Shares
NASDAQ:DLXY
|
N/A |
|
Tevogen Bio Holdings Inc
NASDAQ:TVGN
|
0.466x |
|
DSS Inc
NYSE MKT:DSS
|
-0.290x |
|
Storebrand Global Plus A5
CO:STIGP
|
N/A |
|
Ev Dynamics (Holdings) Limited
PINK:CHDHF
|
0.001x |
|
Borneo Olah Sarana Sukses PT
JK:BOSS
|
0.380x |
Annual Cash Flow Conversion Efficiency for LakeShore Biopharma Co., Ltd (2021–2025)
The table below shows the annual cash flow conversion efficiency of LakeShore Biopharma Co., Ltd from 2021 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $499.75 Million | $-120.98 Million | -0.242x | +52.01% |
| 2024-03-31 | $585.21 Million | $-295.23 Million | -0.504x | -101.40% |
| 2023-03-31 | $728.45 Million | $-182.47 Million | -0.250x | +73.92% |
| 2022-03-31 | $180.68 Million | $-173.55 Million | -0.961x | +99.99% |
| 2021-03-31 | $21.36K | $-246.61 Million | -11543.271x | -- |